

## BCAL DIAGNOSTICS – APPENDIX 4C QUARTERLY ACTIVITIES

- **BCAL lists on the ASX after raising \$10 million**
- **Sydney Breast Clinic has commenced collection of samples as part of Stage 1 of BCAL’s study, which will lead to formal clinical trials and registration of the test for clinical use**
- **Expanding clinical study centres**
- **Recruitment of skilled scientists to accelerate development**
- **USA market entry discussions progressing**

Breast cancer screening and diagnostic company BCAL Diagnostics (ASX:BDX, ‘BCAL’ or the ‘Company’) is pleased to present its quarterly activities report for the quarter ended 30 September 2021.

BCAL is developing a non-invasive laboratory blood test for the detection of breast cancer. The core BCAL technology has evolved from extensive research and investment over approximately ten years by independent groups based in the USA and Australia, who were able to show that breast cancer patient samples contain significantly different lipid profiles from those of both healthy volunteers and breast cancer patients; using a defined methodology. Furthermore, and independently, a team at University of Louisville showed a difference between both those groups and lung cancer patients.

BCAL aims initially to achieve Australian regulatory approval for its breast cancer diagnostic product to complement traditional mammography, seeking to provide physicians with an increase in the sensitivity of breast cancer detection. The test aims to open new approaches to breast cancer screening, including women who self-exclude for religious or other reasons, noting that mammograms can be painful.

BCAL successfully listed on the ASX on 21 July 2021 after raising \$10 million with the issue of 40 million new shares at 25 cents per share. With the issue of new shares, the market capitalisation of the company is approximately \$38.3 million as at the end of the quarter.

During the quarter, BCAL announced one of its clinical partners, Sydney Breast Clinic had commenced collecting samples from patients having mammograms at its CBD location, with 100 samples collected in September. Together with samples from other clinical study centres, these samples will be used to further analyse the initial performance of 18 candidate biomarkers, optimise its algorithm and establish an appropriate workflow.

Other sites collecting samples are either joining or have joined recently, spanning Sydney and Melbourne. BCAL plans to expand clinical study centres. Stage 1 of the diagnostic test program will analyse blood from 1,000 participants.

BCAL executed a Product Development Agreement with IZON during the quarter, who will work with BCAL in the further development of the test. The agreement involves exploration of the development of a bespoke clinical kit, using IZON equipment and components, to accelerate the time for processing clinical samples and providing a format that can be processed rapidly and effectively by pathology laboratories, in a more user-friendly, scalable, standardized and reproducible fashion.

During the quarter, BCAL recruited two highly skilled scientists in support of its product development, with experience in lipidomics, mass spectrometry and data analytics. Dr Cheka Kehelpannala has over 7 years’ experience in lipidomics and analytical chemistry in Australia and Internationally. Dr Mark David is relocating from the UK, and is from the Imperial College London, which is a world leader in research, diagnosis and treatment of diseases. Dr David has over 17 years’ experience in analytical chemistry, metabolomics/lipidomics and mass spectrometry.

Good progress has been made during the quarter on accelerating market entry into the USA. BCAL is in discussion with potential partners who can provide skills to facilitate scientific development, technical support on product development, and commercial input to market entry in relation to billing and reimbursement assistance.

BCAL welcomed Mr Mark Burrows AO to the Board upon listing on 21 July 2021. Mr Burrows has enjoyed a long and distinguished career in investment banking both in Australia and the UK. Mr Burrows has served as a Non-Executive Director on several Australasian and UK public companies including Chairman and Deputy Chair of Brambles, Fairfax Media and Telstra.

Mr Burrows currently retains a role as a senior advisor to UNEP, UNDP, The Green Finance Initiative in London and is on the Asian Council of The Nature Conservancy. He is also a Senior Advisor to the G20 Sustainability Group.

An analysis of cash flows during the quarter are as outlined in the Appendix 4C attached.

Operating cash outflows for the quarter amounted to \$941,000. However, this amount includes costs associated with ASX listing in the amount of \$207,000 and cash outflows relating to annual payments for insurance premiums and ASX annual listing fees.

Fees paid to directors for the quarter, being salary, superannuation and consulting fees, amounted to \$83,000.

This ASX announcement has been approved for release by the Board of BCAL Diagnostics Limited.

ENDS

### Investor & Media Enquiries

Matthew Wright  
NWR Communications  
[matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)  
+61 451 896 420

### About BCAL Diagnostics

BCAL Diagnostics Limited is an Australian screening and diagnostic company committed to the early, accurate diagnosis of breast cancer, and therefore early intervention and improved outcomes for women. Over the past decade BCAL has developed a non-invasive blood test for the detection of breast cancer, with results to date demonstrating 91% specificity and 87% accuracy. The test is initially designed to complement current imaging technologies, such as the mammogram, with the aim of becoming a monitoring and screening tool suitable for women of all ages and backgrounds in any location. With more than two million new cases of breast cancer diagnosed globally each year, a substantial opportunity exists for BCAL to improve patient outcomes. BCAL has partnered with global integrated cancer care and cardiac provider GenesisCare to conduct clinical research required for regulatory approvals across several jurisdictions, commercialisation and market entry points.

Founded in 2010, BCAL is headquartered in Sydney and listed on the Australian Securities Exchange (ASX:BDX). For more information: <https://www.bcaldiagnostics.com/>

## Appendix 4C

### Quarterly cash flow report for entities subject to Listing Rule 4.7B

**Name of entity**

BCAL Diagnostics Limited

**ABN**

97 084 464 193

**Quarter ended ("current quarter")**

30 September 2021

<b>Consolidated statement of cash flows</b>	<b>Current quarter \$A'000</b>	<b>Year to date (3 months) \$A'000</b>
<b>1. Cash flows from operating activities</b>		
1.1 Receipts from customers		
1.2 Payments for		
(a) research and development	(310)	(310)
(b) product manufacturing and operating costs		
(c) advertising and marketing		
(d) leased assets		
(e) staff costs (non R&D)	(13)	(13)
(f) administration and corporate costs	(411)	(411)
1.3 Dividends received (see note 3)		
1.4 Interest received		
1.5 Interest and other costs of finance paid		
1.6 Income taxes paid		
1.7 Government grants and tax incentives		
1.8 Other (provide details if material)		
R&D Tax offset		
Costs associated with ASX Listing	(207)	(207)
<b>1.9 Net cash from / (used in) operating activities</b>	<b>(941)</b>	<b>(941)</b>

<b>2. Cash flows from investing activities</b>		
2.1 Payments to acquire:		
(a) entities		
(b) businesses		
(c) property, plant and equipment		
(d) investments		

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (3 months) \$A'000
(e) intellectual property		
(f) other non-current assets		
2.2 Proceeds from disposal of:		
(a) entities		
(b) businesses		
(c) property, plant and equipment		
(d) investments		
(e) intellectual property		
(f) other non-current assets		
2.3 Cash flows from loans to other entities		
2.4 Dividends received (see note 3)		
2.5 Other (provide details if material)		
<b>2.6 Net cash from / (used in) investing activities</b>		

<b>3. Cash flows from financing activities</b>		
3.1 Proceeds from issues of equity securities (excluding convertible debt securities)	10,000	10,000
3.2 Proceeds from issue of convertible debt securities		
3.3 Proceeds from exercise of options		
3.4 Transaction costs related to issues of equity securities or convertible debt securities	(600)	(600)
3.5 Proceeds from borrowings		
3.6 Repayment of borrowings		
3.7 Transaction costs related to loans and borrowings		
3.8 Dividends paid		
3.9 Other (provide details if material)		
<b>3.10 Net cash from / (used in) financing activities</b>	<b>9,400</b>	<b>9,400</b>

<b>4. Net increase / (decrease) in cash and cash equivalents for the period</b>		
4.1 Cash and cash equivalents at beginning of period	3,408	3,408
4.2 Net cash from / (used in) operating activities (item 1.9 above)	(941)	(941)

<b>Consolidated statement of cash flows</b>		<b>Current quarter \$A'000</b>	<b>Year to date (3 months) \$A'000</b>
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	
4.4	Net cash from / (used in) financing activities (item 3.10 above)	9,400	9,400
4.5	Effect of movement in exchange rates on cash held		
<b>4.6</b>	<b>Cash and cash equivalents at end of period*</b>	<b>11,867</b>	<b>11,867</b>

<b>5.</b>	<b>Reconciliation of cash and cash equivalents</b> at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	<b>Current quarter \$A'000</b>	<b>Previous quarter \$A'000</b>
5.1	Bank balances	1,867	3,408
5.2	Call deposits	10,000	-
5.3	Bank overdrafts		
5.4	Other (provide details)		
<b>5.5</b>	<b>Cash and cash equivalents at end of quarter (should equal item 4.6 above)</b>	<b>11,867</b>	<b>3,408</b>

**6. Payments to related parties of the entity and their associates**

- |   | <b>Current quarter<br/>\$A'000</b> |
|---|------------------------------------|
| 6.1 Aggregate amount of payments to related parties and their associates included in item 1 | 83                                 |
| 6.2 Aggregate amount of payments to related parties and their associates included in item 2 |                                    |

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments

## Quarterly cash flow report for entities subject to Listing Rule 4.7B

**7. Financing facilities**

*Note: the term "facility" includes all forms of financing arrangements available to the entity.*

*Add notes as necessary for an understanding of the sources of finance available to the entity.*

- 7.1 Loan facilities
- 7.2 Credit standby arrangements
- 7.3 Other (please specify)
- 7.4 **Total financing facilities**

Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000

**7.5 Unused financing facilities available at quarter end**


- 7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

**8. Estimated cash available for future operating activities****\$A'000**

8.1	Net cash from / (used in) operating activities (Item 1.9)	(941)
8.2	Cash and cash equivalents at quarter end (Item 4.6)	11,867
8.3	Unused finance facilities available at quarter end (Item 7.5)	
8.4	Total available funding (Item 8.2 + Item 8.3)	11,867
8.5	<b>Estimated quarters of funding available (Item 8.4 divided by Item 8.1)*</b>	12.6

If Item 8.5 is less than 2 quarters, please provide answers to the following questions:

## 8.6

1. Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer: N/A

2. Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer: N/A

3. Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer: N/A

## Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 28 October 2021.....

Authorised by: ..The Board.....  
(Name of body or officer authorising release – see note 4)

## Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.